Literature DB >> 20079529

Ticagrelor in ACS: redefining a new standard of care?

Gregg W Stone1.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20079529     DOI： 10.1016/S0140-6736(10)60070-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

Review 1.  Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.

Authors:  Eitan Abergel; Eugenia Nikolsky
Journal:  Vasc Health Risk Manag       Date:  2010-10-21

2.  Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor.

Authors:  Kade Birkeland; David Parra; Robert Rosenstein
Journal:  J Blood Med       Date:  2010-09-01

3.  Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.

Authors:  Hussam M Tayeb; Adam J Nelson; Scott R Willoughby; Matthew I Worthley
Journal:  Patient Relat Outcome Meas       Date:  2010-12-30

4.  Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.

Authors:  Mingxiang Wen; Yaqi Li; Xiang Qu; Yanyan Zhu; Lingfang Tian; Zhongqin Shen; Xiulin Yang; Xianqing Shi
Journal:  BMC Cardiovasc Disord       Date:  2020-10-01       Impact factor: 2.298
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.